Globally, the prevalence of cancer is increasing, resulting in rising demand for early diagnosis and treatment. According to the National Cancer Institutes, as of January 2019, there were an estimated 16.9 million cancer survivors in the United States alone.
This number is projected to increase to 22.2 million by 2030. Rising prevalence of cancer is expected to create significant demand for multiphoton microscopy across the globe. Fact.MR, in its latest research report, tracks the global sales of multiphoton microscopy in 20+ high-growth markets, with North America and Europe the largest regional markets.
Sample Report –https://factmr.com/connectus/sample?flag=S&rep_id=3405
Key Segments of Multiphoton Microscopy Market
- Two-photon Microscopy
- Three-photon Microscopy
- Skin Imaging
- Deep Tissue Imaging
- Functional and Molecular Imaging
- Intravital Imaging
- Cell Culture
- Hospitals & Clinics
- Clinical & Diagnostic Laboratories
- Academic & Research Institutes
- North America
- Latin America
- South Asia
- East Asia
- Middle East and Africa
Leading players are majorly focused on various market consolidation activities such as mergers, acquisitions, supply distribution partnerships, and launching new products, leading to a high competitiveness in this space.
Players are also striving to provide total solution concepts to customers, especially to hospitals & clinics and academic & research Institutes
- In November 2020, Zeiss Acquired majority stake in Arivis AG. This acquisition is expected to further strengthen the company’s software competencies and market position in 3D image visualization, image processing, and analysis software for research microscopy.
- In 2016, Thorlabs announced that it has entered into a licensing agreement with Howard Hughes Medical Institute (HHMI) for the commercialization of the 2-photon random access mesoscope (2p-RAM), developed at Karel Svoboda’s Janelia Research Campus laboratory of HHMI for in vivo imaging of large brain volumes (up to 5 mm x 1 mm) with single neuron resolution.
- In 2018, Miltenyi Biotec GmbH, a worldwide supplier of products and services to advance biomedical science and cellular therapy, announced that it had acquired LaVision BioTec GmbH, a high-end microscopy specialist.